INFORMATION DISCLOSURE STATEMENT BY APPLICANT

ot 1

Sheet 1

Signature

Application Number	09/687,864	
Filing Date	October 13, 2000	
First Named Inventor	Ledbetter	_
Art Unit	1648	_
Examiner Name	Parkin, Jeffrey S	
Attorney Docket Number	49076.000002.UTL1	

			U. S. PATEN	T DOCUMENTS	
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ^{2 (f Imount)}	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
\angle		^{US-} 5,945,513	08/31/1999	Aruffo et al.	
		^{US-} 5,580,773	12/03/1996	Kang et al.	
*		^{US-} 5,521,288	05/28/1996	Linsley et al.	
		US-			
		US-	<u> </u>		
		US-			
		US-			
		US-			<u> </u>
		US-		 	
		US-	 		

Examiner	Cia-	Finding Date 4.D	IGN PATENT DOCU		
examiner Initials*	Cite No.1	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages
		Country Code ³ Number ⁴ Kind Code ⁸ (if known)	MM-DD-YYYY	replicant of Otoo Document	Or Relevant Figures Appear
		·			
					
	 _				<u> </u>

11/12/04 *EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 'Applicant's unique citation designation number (optional). 'See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. 'Senter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 'For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 'Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.15 if possible. 'Applicant is to place a check mark here if English language

Considered

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

										17	DA
***				_			\sim			PTO/SB/08A (08-00) 31/2002, OMB 0651-0031 TMENT OF COMMERCE	
Please	type a plus :	sign (+)	inside th	is box →			ناً s Pati	Approve And Tradema	ed for use through 10/ ark Office: U.S. DEPAR	31/2002. OMB 0651-0031 TMENT OF COMMERCE alid OMB control number.	1).
•			A.	at of 1995 Ro	nersons are	required to r	espand to a collect	ion of informatio	n unless it contains a v	alid OMB control number.	ヘカ
Under	the Paperw	ork Red	luction Ad	Q 01 1995, 110	-	LER I 3	400 (2)	C	ompi te if Kn wi	<u> </u>	RECEIVED
(Substitu	ite for fo	om 1449	A/PTO	12		Application	o Number	09/687,86	04 £ 2	FI ,O
l		^_	4 A TU	ON DIS	CLOS	BE.	Colication	111111111111111111111111111111111111111	10/13/200	·	
Į.	INF	OKI	ЛАП			THAU	First Name	d inventor	Jeffrey	Ledberger	d 凹
Į	STA	\TE I	MEN	T BY A	PPLIC	ANI	Group Art I		1648		4 2
1				y sheets as			Examiner N				古
L		use	as man		3			ocket Number		600	戶闩
· (Sheet	1	1	of					<u> </u>	9	
`							- TOPE BOOK	MENTS		.90	
Г						U.S. P	ATENT DOCU	Date of Publica	ation of	ges, Columns, Lines. Where Relevant	
T T			U.S. Pa	atent Docume	14GH	e of Patente	ee or Applicant	Cited Docur	nent (Pa	ssages or Relevant	
		Cite No.1	Number	Kind C f (il kno	\ I	of Cited D		MM-DD-YY 10/5/9	07 1670	Figures Appear ρ6.34-65, ρ.9 2-7	=
-	'}	_ b	5596	2406	Armi	tage e	t al.	11/9/9	2 2 21-20	06.34-65,09.2-	\sqcap
-	- Vr -	11	s <u>598</u>	1724	Armi	tage e	t al.	7/30/9	15 1 50	A11 48-56	ŧ
}	-++	— fi	IS 554	0926	Aruf	fo et	al.	12/16	197 Fist 03.1-1	1. P4.1-6, P6.1-16, P6	.53-65, 18.40-4
ł	++		IS 569		Nema	zee e	81.		00 03.40-67	14, 1-B, p4.66-67, p5	<u>:1-1</u> B
ŀ	- 1		IS608		Blun	berg (t al.	8/19/	27 101.13-2	ì	
Ì	$\neg \neg$	h	IS 565	8762	Zane	tti e	<u> </u>	9/15/	00 Fig. 18 F	in 10, p.7 lines 38-67	p. 31 inos 1-37
Ī	AT.		JS611		Blue	estone	et al.	7/1	-		
								 			
ī											
		+									
	├										
	├ ──┼										
	┝╼╾┼										_1
	 +										
	H										
											
					<u> </u>						
								A CHURCHT	· · · · · · · · · · · · · · · · · · ·		
•						FORE	GN PATENT [OCUMENTS	Date of Publication of	Pages, Columns, Lines,	\top
		T		Foreign Pa	atent Docume	int Kind Code ³	Name of Pa Applicant of Cit	Kentee or I	Cited Document	Where Relevant Passages or Relevant	78
•	Examiner Initials	Cite No.1	Office	Numi		(if known)	Applicant of Cit	30 Document	MM-DD-YYYY	Figures Appear	+-1
•		├	1								+-1
	 	├─	╁╌┧								+-1
	 	 	+								11
		+-	+-								
		┼	+						<u> </u>		
		+	1						 		
2 /28/2001 JADDO	1 0000	0004	0968780		<u> </u>				 		
	—	T		0.00 DD					 		
LEC+126			\Box	L							
			سل	<u> </u>						·	
	•			^					3-40 T	1	
	Even	miner	Т	11					Date Considered W.L	2 24	J.
	Sign	nature	1	\sim					and the the thought	cretion if not in conforms	ince and not
	PEYAM!	NER: I	nitial if re	ference cons	idered, wheth	er or not cita	ation is in conforma	nce with MPEP	609. Draw line unrough	catation if not in conforma	
	conside	red. Inc	clude cop	ference cons by of this form	with next co	mmunication	I IC Palent Docum	nents. ³ Enter O	office that issued the do	cument, by the two-letter ust precede the serial	
		مالمالم م	n deeinn	atio U number	2 See attach	nea Kinas oi	U.J. F BOIL DOUG	the mor of the i	reion of the Emperor M	ust precede the sena:	

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² See attached Kinds of U.S. Palent Documents. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box \rightarrow + Under the Paperwork Reduction Act of 1995, no persons are valued to res	Approx Approx Approx Approx Approx	ved for use the bark Office: U. on unless it co
Substitute for form 1449B/PTO	ARI	mplete if
	Application Number	09/68
INFORMATION DISCLOSURE	Filing Date	10/1
STATEMENT BY APPLICANT	First Named Inventor	Jeff

3

(use as many sheets as necessary)

of

2

Sheet

& Patent and Tradema	ed for use through 10/31/2002. OMB 0651-0031 ark Office: U.S. DEPARTMENT OF COMMERCE 1 unless it contains a valid OMB control number.
Alti.	mplete if Known
Application Number	09/687,864
Filing Date	10/13/2000
First Named Inventor	Jeffrey A. Ledbetter
Group Art Unit	1648
Examiner Name	
Attorney Docket Number	

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Examiner initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), data, page(s), volume-issue number(s), publisher, city and/or country where published.	7
$\overline{\lambda}$		HOWELL, A.L., ET AL., "Targeting HIV-1 to FcgammaR on human	Τ
0		phagocytes via bispecific antibodies reduces infectivity of HIV-1 to T cells." J. of Leuk. Biol. 55: 385-391 (1994).	
```		ZACHOUANI, H., ET AL., "Induction of antibodies to the human	t
4		immunodeficiency virus type I by immunization of baboons with immunoglobulin molecules carrying the principal neutralizing	l
7		determinant of the envelope protein." PNAS 92: 631-635 (1995)	
		STRENGELAS, A.D., ET AL., "DNA Immunization induces protective	╀
$\downarrow$		immunity against B-cell lymphoma." Nature Med. 2: 1038-1041 (1996).	l
-4		(1930).	t
			l
$   \langle    \langle    \rangle $		LIU, C., ET AL., "Fcgamma RIII on Human B Cells Can Mediate Enhanced Antigen Presentation." Cell. Immunol. 167: 188-194.	
		(1770)	T
\	$\setminus$	LIU, C., ET AL., "FcgammaRI-Targeted Fusion Proteins Result in	Ī
()		Efficient Presentation by Human Monocytes of Antigenic and Antagonist T Cell Epitopes." J. Clin. Invest. 98: 2001-2007.	
		(1996).	T
			L
$\times$		GUYRE, P.M., ET AL., "Increased Potency of Fc-receptor-targete antigens." Cancer Immunol. Immunother. 45: 146-148 (1997).	ľ
		antigens. Cancer immunor. immunotaer. 45, 140-140 (1997).	
			_
xaminer		Date July and	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include oppy of tylis form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

Consid r d

+

Signature

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Please type a plus sign (+) inside this box -> + + 2  Under the Paperwork Reduction Act of 1995, no persons are instreed to res	Approve	PTO/SB/08B (08-00) of for use through 10/31/2002. OMB 0851-0031 of Office: U.S. DEPARTMENT OF COMMERCE numbers it contains a valid OMB control number.  mpl te if Known	+ACC
Substitute for form 1449B/PTO	Application Number	09/687.864	1 30 C
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	Filing Date First Named Inventor Group Art Unit	10/13/2000 Jeffrey A. Ledbetter	6 700
(use as many sheets as necessary)	Examiner Name		18
Sheet 3 of 3	Attorney Docket Number		180 P. S.
OTHER PRIOR ART - N	ON PATENT LITERATUR	E DOCUMENTS	}
A War and the CARITA	I FITERS), title of the article (w	men appropriate), title of the	i

include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), itself the author (in CAPITAL LETTERS), title of the article (when appropriate), itself the article (when appropriate), its			OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
Cite   No.   Row				_
Cite   No.			include name of the author (in CAPITAL LETTERS), take of the attack (white application) yourne-issue number(s),	T ²
BOYLE, J.S., ET AL., "Enhanced responses to a INA vaccine encoding a fusion antigen that is directed to sites of immune induction." Nature 392: 408-411 (1998).  GUYRE, P.M., ET AL., "Macrophage-targeted killing and vaccines." Res. Immunol. 149: 655-660 (1998).  SERRE, K., ET AL., "Efficient Presentation of MultivalentAntigens Targeted to Various Cell Surface Molecules of Dendritic Cells and Surface Ig of Antigon Specific B Cells." J. Immunol. 161: 6059-6067. (1998).  RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223. (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self	xaminer		item (book, magazine, journal, serial, symposium, cauntry, study, study, serial, symposium, cauntry, study, study, study, study, serial, symposium, cauntry, study,	
encoding a fusion antigen that is directed induction." Nature 392: 408-411 (1998).  GUYRE, P.M., ET AL., "Macrophage-targeted killing and vaccines." Res. Immunol. 149: 655-660 (1998).  SERRE, K., ET AL., "Efficient Presentation of MultivalentAntigens Targeted to Various Cell Surface Molecules of Dendritic Cells and Surface Ig of Antigen Specific B Cells." J. Immunol. 161: 6059-6067. (1998).  RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223. (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self	ritials*	No.1	publisher, dry shout waitly whose persons are a read to a read to a	
encoding a fusion antigen that is directed induction." Nature 392: 408-411 (1998).  GUYRE, P.M., ET AL., "Macrophage-targeted killing and vaccines." Res. Immunol. 149: 655-660 (1998).  SERRE, K., ET AL., "Efficient Presentation of MultivalentAntigens Targeted to Various Cell Surface Molecules of Dendritic Cells and Surface Ig of Antigen Specific B Cells." J. Immunol. 161: 6059-6067. (1998).  RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223. (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self		<del>                                     </del>	POWER IS ET AL., "Enhanced responses to a INA VACCINE	1
GUYRE, P.M., ET AL., "Macrophage-targeted killing and vaccines."  Res. Immunol. 149: 655-660 (1998).  SERRE, K., ET AL., "Efficient Presentation of MultivalentAntigens Targeted to Various Cell Surface Molecules of Dendritic Cells and Surface Ig of Antigen Specific B Cells." J. Immunol. 161.  6059-6067. (1998).  RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223.  (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self		1/1	buying, J.S., Bi and that is directed to sites of immine	ll
GUYRE, P.M., ET AL., "Macrophage-targeted killing and vaccines."  Res. Immunol. 149: 655-660 (1998).  SERRE, K., ET AL., "Efficient Presentation of MultivalentAntigens Targeted to Various Cell Surface Molecules of Dendritic Cells and Surface Ig of Antigen Specific B Cells." J. Immunol. 161.  6059-6067. (1998).  RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223.  (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self		۲ ۱	encoding a fusion antigen that is (1009)	
GUYRE, P.M., ET AL., "Macrophage-targeted killing and vaccines."  Res. Immunol. 149: 655-660 (1998).  SERRE, K., ET AL., "Efficient Presentation of MultivalentAntigens Targeted to Various Cell Surface Molecules of Dendritic Cells and Surface Ig of Antigen Specific B Cells." J. Immunol. 161: 6059-6067. (1998).  RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enbances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223. (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self		ll	Anduction " Nature 392: 408-411 (1990).	1
Res. Immunol. 149: 055-000 (1990).  SERRE, K., ET AL., "Efficient Presentation of MultivalentAntigens Targeted to Various Cell Surface Molecules of Dendritic Cells and Surface Ig of Antigen Specific B Cells." J. Immunol. 161: 6059-6067. (1998).  RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223. (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self		-	THILL COMPANY	li
Res. Immunol. 149: 055-000 (1990).  SERRE, K., ET AL., "Efficient Presentation of MultivalentAntigens Targeted to Various Cell Surface Molecules of Dendritic Cells and Surface Ig of Antigen Specific B Cells." J. Immunol. 161: 6059-6067. (1998).  RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223. (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self		1 1		1 '
Res. Immunol. 149: 055-000 (1990).  SERRE, K., ET AL., "Efficient Presentation of MultivalentAntigens Targeted to Various Cell Surface Molecules of Dendritic Cells and Surface Ig of Antigen Specific B Cells." J. Immunol. 161: 6059-6067. (1998).  RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223. (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self				<b>!</b>
Res. Immunol. 149: 055-000 (1990).  SERRE, K., ET AL., "Efficient Presentation of MultivalentAntigens Targeted to Various Cell Surface Molecules of Dendritic Cells and Surface Ig of Antigen Specific B Cells." J. Immunol. 161: 6059-6067. (1998).  RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223. (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self		1	"We have targeted killing and vaccines	i • ''
Res. Immunol. 149: 055-000 (1990).  SERRE, K., ET AL., "Efficient Presentation of MultivalentAntigens Targeted to Various Cell Surface Molecules of Dendritic Cells and Surface Ig of Antigen Specific B Cells." J. Immunol. 161: 6059-6067. (1998).  RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223. (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self			CHYRE, P.M., ET AL., "Macrophage-talgettal	1
SERRE, K., ET AL., "Efficient Presentation of MultivalentAntigens Targeted to Various Cell Surface Molecules of Dendritic Cells and Surface Ig of Antigen Specific B Cells." J. Immunol. 161: 6059-6067. (1998).  RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enbances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223. (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self		l /	Real Temporal 149: 655-660 (1998).	l '
Targeted to Various tell Sulface in J. Immunel. 161:  and Surface Ig of Antigen Specific B Colls." J. Immunel. 161:  6059-6067. (1998).  RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223.  (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self	$\sim$	V	Res. Immediate.	╁┈╌
Targeted to Various tell Sulface in J. Immunel. 161:  and Surface Ig of Antigen Specific B Colls." J. Immunel. 161:  6059-6067. (1998).  RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223.  (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self		1	Description of MultivalentAntig	cens
Targeted to Various tell Sulface in J. Immunel. 161:  and Surface Ig of Antigen Specific B Colls." J. Immunel. 161:  6059-6067. (1998).  RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223.  (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self			SERRE K. ET AL. "Efficient Presentation of Dendritic Cells	1
and Surface Ig of Antigen Specific 5 502157  6059-6067. (1998).  RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223.  (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self	/	V	Targeted to Various Cell Surface Molecules of Dentilities	.1
RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223.  (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self		7	Targeted to Target Specific B Colley" Jy Immunoly 101	┪
RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223.  (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self		4	and Surface 18 of whiteson products a	1
RODRIGUEZ, D., ET AL., "A human immunodeficiency virus type 1 Env-granulocyte macrophage colony-stimulating factor fusion protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223.  (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self		1	\ 6050_6067. (1998).	1
Env-granulocyte macrophage colong-weight macrophage colong-weight macrophage to Env in a protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223.  (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self macrophage colong." J. of Gen Virol. 80: 217-223.		1	10039 00011 (=35.7)	Ι.
Env-granulocyte macrophage colong-weight macrophage colong-weight macrophage to Env in a protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223.  (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self macrophage colong." J. of Gen Virol. 80: 217-223.		1		4
Env-granulocyte macrophage colong-weight macrophage colong-weight macrophage to Env in a protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223.  (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self macrophage colong." J. of Gen Virol. 80: 217-223.		+-	"A human immunodeficiency virus type	4
Env-granulocyte macrophage colong-weight macrophage colong-weight macrophage to Env in a protein enhances the cellular immune response to Env in a vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223.  (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self macrophage colong." J. of Gen Virol. 80: 217-223.		1/	RODRIGUEZ, D., El Ab., and any off muleting factor fusion	
protein enhances the certural ruman vaccinia virus-based vaccine." J. of Gen Virol. 80: 217-223.  (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self	<i>₩</i>	X	Env-granulocyte macrophage colony-stimum to Env in a	l
vaccinia virus-based vaccine. 3. of den 12200.  (1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self	1	, f	and an enhances the cellular immune response to any	2
(1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self		+	protein emparate " J. of Gen Virol. 80: 217-22	가
(1999).  BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a self		1	vaccinia virus-based vaccine.	1
BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a sell		1	l control of the cont	ı
BIRAGYN, A., ET AL., "Genetic fusion of chemokines to a sell		1	(1999).	┰
BIRAGYN, A., ET AL., "Genetic lustral dependent antitumor tumor antigen induces protective, T-cell dependent antitumor tumor antigen induces protective, T-cell dependent antiqual antigen induces protective, T-cell dependent antiqual antigen induces protective, T-cell dependent antiqual		4-	to a sell	1
tumor antigen induces protective, T-cell dependent and the state of th		1	BTRAGYN. A. ET AL., "Genetic Tusion"	1
tuant and got levels 17: 253-258. (1999).		-1/-	Aumor entiren induces protective, T-cell dependent	- 1
Immunity I Nature Diececin		И	tumor and the Blotsch 17+ 253-258 (1999)	Τ.
	<u> </u>	-₩-	1 1 mmunity - Nature Divocut	- }
	l	1		ł
		1		
	1	- 1		
		+		- [
	l	- 1		1
	1	-1		- 1
	1	1	1	1
	Į.			l
	1	- 1		
		4-		1
	1	l	l	l
	1	-	<b>[</b>	- 1
	I	- [	i	- 1
	1	- 1		ı
	1	1		.
	ł	- 1		-
	<u> </u>			

Date Examiner Consid red

*EXAMINER: Initial it reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U. S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English tanguage Translation is attached.